DANIELI CASTRO OLIVEIRA DE ANDRADE

(Fonte: Lattes)
Índice h a partir de 2011
19
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Revista / Livro: Annals of the Rheumatic Diseases ×

Resultados de Busca

Agora exibindo 1 - 6 de 6
  • conferenceObject
    CLINICAL AND SEROLOGICAL COMPARATIVE ANALYSIS OF SYSTEMIC SCLEROSIS WITH OR WITHOUT OVERLAP SYNDROMES IN A LARGE BRAZILIAN COHORT
    (2014) SILVA, C. M.; VIANA, V. S.; PASOTO, S. G.; SEGURO, L. P.; ANDRADE, D. C. O.; BONFA, E.; SAMOIO-BARROS, P. D.
  • article 29 Citação(ões) na Scopus
    Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
    (2022) AIKAWA, Nadia Emi; KUPA, Leonard de Vinci Kanda; MEDEIROS-RIBEIRO, Ana Cristina; SAAD, Carla Goncalves Schahin; YUKI, Emily Figueiredo Neves; PASOTO, Sandra Gofinet; ROJO, Priscila Tagliaferro; PEREIRA, Rosa Maria Rodrigues; SHINJO, Samuel Katsuyuki; SAMPAIO-BARROS, Percival Degrava; ANDRADE, Danieli Castro Oliveira; HALPERN, Ari Stiel Radu; FULLER, Ricardo; SOUZA, Fernando Henrique Carlos; GUEDES, Lissiane Karine Noronha; ASSAD, Ana Paula Luppino; MORAES, Julio Cesar Bertacini de; LOPES, Michelle Remiao Ugolini; MARTINS, Victor Adriano de Oliveira; BETANCOURT, Lorena; RIBEIRO, Carolina Torres; SALES, Lucas Peixoto; BERTOGLIO, Isabela Maria; BONOLDI, Virginia Lucia Nazario; MELLO, Renata Lys Pinheiro; BALBI, Gustavo Guimaraes Moreira; SARTORI, Ana Marli Christovam; ANTONANGELO, Leila; SILVA, Clovis Artur; BONFA, Eloisa
    Objective To determine the immunogenicity of the third dose of CoronaVac vaccine in a large population of patients with autoimmune rheumatic diseases (ARD) and the factors associated with impaired response. Methods Adult patients with ARD and age-balanced/sex-balanced controls (control group, CG) previously vaccinated with two doses of CoronaVac received the third dose at D210 (6 months after the second dose). The presence of anti-SARS-CoV-2 S1/S2 IgG and neutralising antibodies (NAb) was evaluated previously to vaccination (D210) and 30 days later (D240). Patients with controlled disease suspended mycophenolate mofetil (MMF) for 7 days or methotrexate (MTX) for 2 weekly doses after vaccination. Results ARD (n=597) and CG (n=199) had comparable age (p=0.943). Anti-S1/S2 IgG seropositivity rates significantly increased from D210 (60%) to D240 (93%) (p<0.0001) in patients with ARD. NAb positivity also increased: 38% (D210) vs 81.4% (D240) (p<0.0001). The same pattern was observed for CG, with significantly higher frequencies for both parameters at D240 (p<0.05). Multivariate logistic regression analyses in the ARD group revealed that older age (OR=0.98, 95% CI 0.96 to 1.0, p=0.024), vasculitis diagnosis (OR=0.24, 95% CI 0.11 to 0.53, p<0.001), prednisone >= 5 mg/day (OR=0.46, 95% CI 0.27 to 0.77, p=0.003), MMF (OR=0.30, 95% CI 0.15 to 0.61, p<0.001) and biologics (OR=0.27, 95% CI 0.16 to 0.46, p<0.001) were associated with reduced anti-S1/S2 IgG positivity. Similar analyses demonstrated that prednisone >= 5 mg/day (OR=0.63, 95% CI 0.44 to 0.90, p=0.011), abatacept (OR=0.39, 95% CI 0.20 to 0.74, p=0.004), belimumab (OR=0.29, 95% CI 0.13 to 0.67, p=0.004) and rituximab (OR=0.11, 95% CI 0.04 to 0.30, p<0.001) were negatively associated with NAb positivity. Further evaluation of COVID-19 seronegative ARD at D210 demonstrated prominent increases in positivity rates at D240 for anti-S1/S2 IgG (80.5%) and NAb (59.1%) (p<0.0001). Conclusions We provide novel data on a robust response to the third dose of CoronaVac in patients with ARD, even in those with prevaccination COVID-19 seronegative status. Drugs implicated in reducing immunogenicity after the regular two-dose regimen were associated with non-responsiveness after the third dose, except for MTX.
  • conferenceObject
  • conferenceObject
    PREDICTORS TO PROGRESSION TO SYSTEMIC SCLEROSIS IN A GROUP OF SECONDARY RAYNAUD PHENOMENON OBSERVED IN A LARGE SINGLE BRAZILIAN COHORT
    (2020) SIQUEIRA, V.; HELBINGEN, M.; LUPPINO-ASSAD, A. P.; SILVA, H. Carrico Da; ANDRADE, D.; MEDEIROS-RIBEIRO, A. C.; SAMPAIO-BARROS, P. D.
  • conferenceObject
    REASONS FOR BREASTFEEDING AVOIDANCE: A MULTICENTER INSIGHT IN MOTHERS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    (2023) FODDAI, S. G.; RADIN, M.; SCHREIBER, K.; CECCHI, I.; SIGNORELLI, F.; JESUS, G. De; ASO, K.; KONO, M.; URBAN, M. L.; BACCO, B.; CASSARINO, S. Gallo; SARDO, L. Lo; ARBRILE, M.; BARINOTTI, A.; GOMEZ-GARCIA, I.; QUAGLIA, M. I.; TISSERA, Y.; AGUIRRE-ZAMORANO, M. A.; ALBA, P.; BENEDETTO, C.; ATSUMI, T.; AMENGUAL, O.; EMMI, G.; ANDRADE, D.; MAROZIO, L.; ROCCATELLO, D.; SCIASCIA, S.
  • article 56 Citação(ões) na Scopus
    2023 ACR/EULAR antiphospholipid syndrome classification criteria
    (2023) BARBHAIYA, Medha; ZUILY, Stephane; NADEN, Ray; HENDRY, Alison; MANNEVILLE, Florian; AMIGO, Mary-Carmen; AMOURA, Zahir; ANDRADE, Danieli; ANDREOLI, Laura; ARTIM-ESEN, Bahar; ATSUMI, Tatsuya; AVCIN, Tadej; BELMONT, Michael H.; BERTOLACCINI, Maria Laura; BRANCH, D. Ware; CARVALHEIRAS, Graziela; CASINI, Alessandro; CERVERA, Ricard; COHEN, Hannah; COSTEDOAT-CHALUMEAU, Nathalie; CROWTHER, Mark; JESUS, Guilherme de; DELLUC, Aurelien; DESAI, Sheetal; SANCHO, Maria De; DEVREESE, Katrien M.; DIZ-KUCUKKAYA, Reyhan; DUARTE-GARCIA, Ali; FRANCES, Camille; GARCIA, David; GRIS, Jean-Christophe; JORDAN, Natasha; LEAF, Rebecca K.; KELLO, Nina; KNIGHT, Jason S.; LASKIN, Carl; LEE, Alfred I.; LEGAULT, Kimberly; LEVINE, Steve R.; LEVY, Roger A.; LIMPER, Maarten; LOCKSHIN, Michael D.; MAYER-PICKEL, Karoline; MUSIAL, Jack; MERONI, Pier Luigi; ORSOLINI, Giovanni; ORTEL, Thomas L.; PENGO, Vittorio; PETRI, Michelle; PONS-ESTEL, Guillermo; GOMEZ-PUERTA, Jose A.; RAIMBOUG, Quentin; ROUBEY, Robert; SANNA, Giovanni; SESHAN, Surya V.; SCIASCIA, Savino; TEKTONIDOU, Maria G.; TINCANI, Angela; WAHL, Denis; WILLIS, Rohan; YELNIK, Cecile; ZUILY, Catherine; GUILLEMIN, Francis; COSTENBADER, Karen; ERKAN, Doruk
    Objective To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods This international multidisciplinary initiative included four phases: (1) Phase I, criteria generation by surveys and literature review; (2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; (3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and (4) Phase IV, validation using independent adjudicators' consensus as the gold standard. Results The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion, followed by additive weighted criteria (score range 1-7 points each) clustered into six clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and two laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-beta(2)-glycoprotein I antibodies). Patients accumulating at least three points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria vs the 2006 revised Sapporo classification criteria had a specificity of 99% vs 86%, and a sensitivity of 84% vs 99%. Conclusion These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.